SIRT1 and non-small cell lung carcinoma: Furthermore, SIRT1 is a potential predictor of poor prognosis in NSCLC patients treated with platinum-based chemotherapy, and SIRT1 downregulation greatly increases chemosensitivity to cisplatin, indicating the important role of SIRT1 in driving lung cancer development and chemoresistance.